Aptalis

Aptalis was a pharmaceutical company formed in 2011 through the merger of Axcan Pharma and Eurand Pharmaceuticals. The company focused on specialty medicines, particularly treatments for gastrointestinal disorders, cystic fibrosis-related pancreatic insufficiency, and other conditions addressed through differentiated drug-delivery technologies. Its predecessor businesses combined commercial pharmaceutical operations with formulation and contract-manufacturing capabilities, giving Aptalis a portfolio that included pancrelipase products, gastrointestinal therapies, and modified-release or taste-masked dosage forms. Axcan brought expertise in gastrointestinal medicine. Before being acquired by private-equity firm TPG Capital in 2008, it had operated as a publicly traded company on NASDAQ. Eurand was known for pharmaceutical formulation technologies, including sustained-release systems and taste-masking approaches, as well as for manufacturing services. Both predecessor companies had developed and marketed pancrelipase products, which are used to manage exocrine pancreatic insufficiency, including the pancreatic complications associated with cystic fibrosis. Their combination created a specialty pharmaceutical company with both branded medicines and technical development capabilities. Aptalis expanded its commercial portfolio during the early 2010s. In June 2011, it received United States Food and Drug Administration approval for a lower-strength formulation of ZENPEP pancrelipase capsules intended for infants with exocrine pancreatic insufficiency associated with cystic fibrosis. In January 2012, the company announced an agreement to market RECTIV, a nitroglycerin ointment for the treatment of anal fissures in the United States. The same month, Aptalis announced that partner Gilead Sciences had received approval for an oral powder formulation of Viread, a tenofovir disoproxil product. In September 2013, Aptalis launched PYLERA capsules, a combination of bismuth subcitrate, metronidazole, and tetracycline used with omeprazole in the treatment of Helicobacter pylori infection. Aptalis was acquired by Forest Laboratories in January 2014. Reference accounts describe the transaction as a cash acquisition, with reported values differing between sources: the Wikipedia account identifies a value of approximately $675 million, while the supplied reference material reports Forest's announced agreement at $2.9 billion. Because the figures are inconsistent, they should not be treated as a single verified valuation without reviewing the original transaction filings and announcements. The acquisition also caused Aptalis to withdraw a planned initial public offering. Forest Laboratories was subsequently acquired by Actavis, which later became part of Allergan. The Aptalis name did not remain the long-term identity of the acquired operations. In April 2015, TPG Capital acquired Aptalis Pharmaceutical Technologies, and that business was renamed Adare Pharmaceuticals. In 2020, Thomas Lee Partners and Frazier Healthcare Partners acquired Adare Pharmaceuticals, which subsequently developed into a contract development and manufacturing organization and was rebranded as Adare Pharma Solutions. Aptalis is therefore best understood as a defunct specialty pharmaceutical company whose assets and technical operations continued under successor ownership and brands.

Aptalis emerged from the combination of two pharmaceutical businesses with complementary strengths. Axcan Pharma specialized in gastrointestinal disorders and had developed a presence in specialty medicines, including pancrelipase therapies. Eurand Pharmaceuticals focused on pharmaceutical formulation and manufacturing technologies, particularly sustained-release and taste-masked dosage forms. Both companies produced and marketed pancrelipase products used to address exocrine pancreatic insufficiency, including symptoms and complications associated with cystic fibrosis. Axcan had previously operated as a public company listed on NASDAQ before TPG Capital acquired it in 2008. Eurand contributed formulation science and contract-manufacturing expertise. Their merger in 2011 created Aptalis, a company positioned between a specialty pharmaceutical marketer and a technology-oriented pharmaceutical developer. The combination gave Aptalis a portfolio spanning branded medicines, gastrointestinal treatments, cystic-fibrosis-related products, and delivery platforms intended to improve dosing, release characteristics, or patient acceptability. The newly formed company continued to develop and commercialize medicines in targeted therapeutic areas. In June 2011, Aptalis obtained FDA approval for a low-strength version of ZENPEP pancrelipase capsules intended for infants with exocrine pancreatic insufficiency caused by cystic fibrosis. The formulation broadened the product's suitability for a particularly young patient population. In January 2012, Aptalis announced a United States marketing agreement for RECTIV, an ointment used to treat anal fissures. It also announced that Gilead Sciences, its partner, had received approval for an oral powder formulation of Viread. In September 2013, Aptalis launched PYLERA capsules, a three-drug combination of bismuth subcitrate, metronidazole, and tetracycline. Used together with omeprazole, PYLERA was indicated for patients with Helicobacter pylori infection. Aptalis pursued a public-market path but abandoned its planned initial public offering after Forest Laboratories announced an agreement to acquire the company in January 2014. The acquisition marked the end of Aptalis as an independent pharmaceutical company. The supplied reference accounts report conflicting transaction values: the Wikipedia entry describes a value of $675 million, while another supplied account reports a $2.9 billion cash agreement. The discrepancy is unresolved in the available material and may reflect different definitions of transaction value or a source error. Forest Laboratories later became part of the corporate lineage that included Actavis and Allergan. The acquired operations subsequently split into successor identities. In April 2015, TPG Capital acquired Aptalis Pharmaceutical Technologies and renamed it Adare Pharmaceuticals. Adare later changed ownership again in 2020 when Thomas Lee Partners and Frazier Healthcare Partners acquired the business. The successor organization evolved toward the contract development and manufacturing organization model and was ultimately rebranded as Adare Pharma Solutions, headquartered in Lawrenceville, New Jersey. Thus, Aptalis no longer operates as a standalone brand, but its formulation, manufacturing, and specialty-pharmaceutical activities continued through successor businesses.

1. 2020Adare changes ownership and expands CDMO orientation

   Thomas Lee Partners and Frazier Healthcare Partners acquired Adare Pharmaceuticals, which subsequently operated as a contract development and manufacturing organization.

   Source
2. 2015Aptalis Pharmaceutical Technologies becomes Adare Pharmaceuticals

   Following a TPG Capital acquisition, Aptalis Pharmaceutical Technologies was renamed Adare Pharmaceuticals.

   Source
3. 2014Forest Laboratories agrees to acquire Aptalis

   Forest Laboratories announced an agreement to acquire Aptalis, ending its independence and prompting withdrawal of its planned IPO.

   Source
4. 2013PYLERA launched

   Aptalis launched PYLERA capsules for use with omeprazole in treating Helicobacter pylori infection.

   Source
5. 2012RECTIV marketing agreement announced

   Aptalis announced an agreement to market RECTIV in the United States for anal fissure treatment.

   Source
6. 2011Aptalis is created

   Eurand Pharmaceuticals and Axcan Pharma merged to form Aptalis.

   Source
7. 2011ZENPEP infant formulation approved

   A low-strength ZENPEP formulation for infants with cystic-fibrosis-related exocrine pancreatic insufficiency received FDA approval.

   Source
8. 2008TPG Capital acquires Axcan

   TPG Capital acquired Axcan Pharma, one of the predecessor businesses that later contributed to Aptalis.

   Source

A specialty pharmaceutical company centered on gastrointestinal and cystic-fibrosis-related therapies, supported by differentiated drug-delivery technologies and pharmaceutical development capabilities.

• ZENPEPPancreatic enzyme replacement therapy2011

  ZENPEP is a pancrelipase product used to manage exocrine pancreatic insufficiency. Aptalis received FDA approval in 2011 for a lower-strength capsule formulation intended for infants with exocrine pancreatic insufficiency associated with cystic fibrosis. The product represented one of Aptalis's principal specialty-medicine offerings and reflected the shared pancrelipase heritage of its Axcan and Eurand predecessor businesses.

• RECTIVGastrointestinal medicine2012

  RECTIV is a nitroglycerin ointment used in the treatment of anal fissures. Aptalis announced an agreement to market the product in the United States in January 2012. It broadened Aptalis's gastrointestinal portfolio beyond pancreatic enzyme replacement and illustrated the company's strategy of building a focused specialty-medicine business through licensing and marketing arrangements.

• PYLERAHelicobacter pylori eradication therapy2013

  PYLERA capsules combine bismuth subcitrate, metronidazole, and tetracycline. The regimen is used with omeprazole for patients with Helicobacter pylori infection. Aptalis launched PYLERA in September 2013, adding a combination gastrointestinal anti-infective therapy to its specialty pharmaceutical portfolio shortly before the company's acquisition by Forest Laboratories.

• Viread oral powder formulationAntiviral formulation partnership2012

  The oral powder formulation of Viread was developed and commercialized through Aptalis's partnership with Gilead Sciences. Gilead received approval for the formulation in January 2012. The product demonstrates Aptalis's role not only as a direct marketer of specialty medicines but also as a formulation and development partner for other pharmaceutical companies.

• 2015Separate and rename Aptalis Pharmaceutical TechnologiesStrategy

  Following Forest Laboratories' acquisition of Aptalis, the pharmaceutical technology operations continued under separate ownership.

  What changed. TPG Capital acquired Aptalis Pharmaceutical Technologies and renamed it Adare Pharmaceuticals.

  Aftermath. The successor business increasingly emphasized pharmaceutical development and manufacturing services rather than the Aptalis corporate identity.

  Source
• 2014Accept Forest Laboratories acquisitionM&A

  Aptalis was pursuing an initial public offering but received an acquisition proposal from Forest Laboratories.

  What changed. Aptalis agreed to be acquired by Forest Laboratories for cash and withdrew its planned IPO.

  Aftermath. Aptalis ceased to operate as an independent company. Available reference accounts report conflicting transaction values, so the valuation requires further verification.

  Reported acquisition value. $675 million in one reference account; $2.9 billion in the supplied reference material (January 2014)

  Source
• 2011Merge Axcan Pharma and Eurand PharmaceuticalsM&A

  Axcan and Eurand had complementary positions in specialty pharmaceuticals, gastrointestinal medicines, pancrelipase products, and pharmaceutical formulation technologies.

  What changed. The predecessor companies merged to establish Aptalis.

  Aftermath. The merger created a combined specialty pharmaceutical and formulation business that expanded its portfolio through launches and partnerships.

  Source

• 2020Adare Pharmaceuticals acquired by Thomas Lee Partners and Frazier Healthcare

  Thomas Lee Partners and Frazier Healthcare Partners acquired Adare Pharmaceuticals, supporting its subsequent development as a contract development and manufacturing organization.

  M&A
  Source
• 2015Aptalis Pharmaceutical Technologies renamed Adare Pharmaceuticals

  TPG Capital acquired Aptalis Pharmaceutical Technologies and changed its name to Adare Pharmaceuticals.

  M&ALeadership change
  Source
• 2014Forest Laboratories agrees to acquire Aptalis

  Forest Laboratories announced an agreement to acquire Aptalis in cash. The transaction led Aptalis to withdraw its proposed initial public offering.

  M&A
  Source
• 2013Aptalis launches PYLERA capsules

  Aptalis launched PYLERA, a combination of bismuth subcitrate, metronidazole, and tetracycline used with omeprazole against Helicobacter pylori infection.

  Product launch
  Source
• 2012Aptalis announces United States marketing agreement for RECTIV

  The company announced an agreement to market RECTIV, an ointment for the treatment of anal fissures, in the United States.

  Product launch
  Source
• 2012Gilead receives approval for Viread oral powder formulation

  Aptalis reported that its partner Gilead Sciences had received approval for an oral powder formulation of Viread, a tenofovir disoproxil product.

  Product launch
  Source
• 2011Aptalis formed through the merger of Axcan Pharma and Eurand Pharmaceuticals

  Axcan Pharma and Eurand Pharmaceuticals combined to create Aptalis, bringing together gastrointestinal medicines, pancrelipase products, and formulation technologies.

  M&AOther
  Source
• 2011FDA approves low-strength ZENPEP for infants

  Aptalis received United States approval for a lower-strength ZENPEP pancrelipase capsule formulation for infants with exocrine pancreatic insufficiency associated with cystic fibrosis.

  Product launchRegulation
  Source

1. Aptalis